International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer
Primary Goal: To compare overall survival at 3 years.
1. To compare disease specific survival at 3 years.
2. To compare 3 year progression free survival at the treated primary tumor site
3. To compare grade 3 and above acute and/or chronic toxicities.
4. To evaluate predictive value of pre and post treatment PET scan in clinical outcome.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Jack Roth, M.D.
M.D. Anderson Cancer Center
United States: Institutional Review Board
|Central Baptist Hospital||Lexington, Kentucky 40503|
|Advocate Christ Medical Center||Oak Lawn, Illinois 60453|
|Penrose Cancer Center||Colorado Springs, Colorado 80933|
|St. Joseph Mercy Hospital||Pontiac, Michigan 48341-2985|
|Saint Louis University||St. Louis, Missouri 63104|
|U.T. M.D. Anderson Cancer Center||Houston, Texas 77030|
|St. Luke's Episcopal Hospital||Houston, Texas 77030|
|Jupiter Medical Center||Jupiter, Florida 33458|
|Community Regional Medical Center||Fresno, California 93721|
|Denver CyberKnife||Lone Tree, Colorado 80124|
|Parkview Cancer Center||Fort Wayne, Indiana 46845|
|St. Mary's of Michigan||Saginaw, Michigan|
|St. Mary's Duluth Clinic Health System||Duluth, Minnesota 55805|
|St. Mary's||Reno, Nevada 89503|